Clinical Guides
Childhood Eczema (Atopic Dermatitis)
A source-grounded guide to childhood atopic dermatitis assessment, skin-barrier care, anti-inflammatory treatment and escalation, with Indian context and mandatory review.
MedNext Academy | 12 min read
Childhood Eczema (Atopic Dermatitis)
A source-grounded guide to childhood atopic dermatitis assessment, skin-barrier care, anti-inflammatory treatment and escalation, with Indian context and mandatory review.
Summary
Atopic dermatitis is a chronic, itchy, relapsing inflammatory skin disorder. Age-specific distribution, xerosis, excoriation and a personal or family atopic history support diagnosis, but there is no single diagnostic blood test. Infants often have facial and extensor disease; older children commonly develop flexural eczema. Severity includes both visible extent and the child's itch, sleep, pain, school attendance and family burden.
Daily care combines a fragrance-free emollient, gentle washing, trigger avoidance and timely topical anti-inflammatory treatment. Topical corticosteroids are selected by site, age and flare severity and are safe when correctly prescribed; undertreatment prolongs inflammation and barrier failure. Topical calcineurin inhibitors can be steroid-sparing at sensitive sites under an appropriate protocol. Routine antibiotics, antiseptic baths, sedating antihistamines and elimination diets are not general eczema treatment.
Crusting and weeping can reflect bacterial infection, but not every flare needs antibiotics. Painful monomorphic vesicles or punched-out erosions, fever or rapid worsening raises eczema herpeticum and requires same-day emergency assessment. Poor growth, recurrent infection, unusual distribution or treatment failure should reopen diagnosis and adherence assessment. Moderate-to-severe disease unresponsive to optimised topical care warrants specialist review for phototherapy or systemic therapy.
This guide uses IAP skin-care recommendations for Indian context, current guidelines' updated stepped-care framework and the 2026 AAD paediatric guideline as an international comparator. Advanced medicines have changing age approvals and access in India, so no product is assumed available. The quarantined draft is reviewed and has been reviewed by the MedNext Clinical Team.
How Common Is It?
Atopic dermatitis is one of the commonest inflammatory disorders of childhood. Reported prevalence varies by age, diagnostic definition, climate, urbanisation and study method. Questionnaire-defined symptoms are not equivalent to a clinician-confirmed diagnosis, and tertiary dermatology clinics overrepresent severe disease. This guide therefore does not assign a single current Indian prevalence figure.
Disease often begins in infancy or early childhood. Many children improve with age, but remission is not guaranteed and relapse can occur. The course is heterogeneous: some have intermittent localised flares, others persistent widespread inflammation with sleep loss and infection. Visible body-surface area alone underestimates burden when hands, face, genital skin or sleep are severely affected.
Eczema is associated with other atopic disorders, including food allergy, asthma and allergic rhinitis, but the sequence called the atopic march is not inevitable. Sensitisation tests can be positive without clinical allergy. Treating eczema is important for comfort and barrier restoration, but families should not be promised that skin treatment will prevent all later allergy or asthma.
In Indian practice, heat, sweating, water hardness, air pollution, crowded living, product advertising and cost can shape symptoms and adherence. These factors do not establish cause in an individual child. Clinicians should measure current control through itch, sleep, flares, treatment days, school impact and infection rather than comparing families with uncertain population estimates.
Risk Factors
Genetic barrier dysfunction, immune dysregulation and environmental exposure interact in atopic dermatitis. Family history of eczema, asthma or allergic rhinitis increases likelihood. Filaggrin variants are important in some populations but routine genetic testing is not needed. Dry climate, low humidity, harsh cleansers, fragrance, wool, friction, heat and sweating can worsen symptoms; triggers vary and should be identified by reproducible history.
Food allergy is more common in children with early severe eczema, yet food is not the usual cause of every flare. Unsupervised milk, egg, wheat or multiple-food exclusion can impair growth and create anxiety. Test only when there is a convincing immediate reaction or specialist-defined question; interpret sensitisation in clinical context. Aeroallergen testing likewise should change a practical plan.
Bacterial colonisation is common on inflamed skin, but colonisation does not equal infection. Scratching, fissures and undertreated inflammation increase secondary infection. Herpes simplex exposure can cause eczema herpeticum. Sleep deprivation intensifies itch and family stress, while bullying and visible facial disease affect mental health.
Treatment risks include potent steroid on thin skin, prolonged unsupervised use, use of topical calcineurin inhibitor on active infection, and unregulated combination creams. The opposite risk, corticosteroid phobia, leads to inadequate treatment and repeated flares. Ask what was actually applied, how much, to which site and for how long before labelling disease resistant.
Diagnosis
Diagnosis is clinical and should document morphology, distribution, chronicity, itch and effect on daily life. Severity tools can support monitoring but do not replace examination.
History
Ask about onset, itch, sleep, pain, flare frequency, sites, wet work, heat, sweat, clothing, cleansers and treatments. Record immediate food reactions separately from delayed perceived flares. Review asthma, rhinitis, infection, herpes exposure, growth, school and family burden. Ask exactly which creams, strengths and quantities were used and whether cost, fear, language or complexity limited adherence.
Examination
Inspect all skin, including face, folds, hands, feet and nappy area. Note xerosis, erythema, papules, lichenification, excoriation, fissures, oozing, crust, pustules, vesicles and punched-out erosions. Assess body-surface extent and sensitive sites, then look for fever, lymphadenopathy, dehydration, growth faltering, eye involvement and signs of scabies or contact allergy. Photographs with consent can track change.
Investigations
No routine laboratory test confirms eczema. Swab only when infection is severe, recurrent, unusual or not responding. Viral sampling supports suspected eczema herpeticum but treatment must not await a delayed result. Allergy testing is targeted to a convincing immediate reaction or specialist question, not used as a screening panel. Patch testing may help suspected contact allergy. CBC, immunology, nutritional tests or biopsy are reserved for atypical disease, poor growth, recurrent infection or diagnostic uncertainty.
Differential Diagnosis
Seborrhoeic dermatitis begins early, often affects scalp and folds, and is usually less itchy. Irritant or allergic contact dermatitis follows exposure and distribution; patch testing can clarify persistent suspected allergy. Scabies causes intense nocturnal itch, characteristic sites and affected contacts. Psoriasis produces sharply demarcated plaques and may involve scalp, nails or nappy folds with less scale under occlusion.
Tinea can form annular scaly plaques and becomes distorted by topical steroid. Impetigo causes crust and pustules; widespread painful monomorphic vesicles or punched-out erosions suggests eczema herpeticum. Molluscum may trigger surrounding eczema but is not itself an eczema flare. Hand-foot-and-mouth disease and varicella have systemic and distributional clues.
In infants, food-protein disorders can coexist with eczema but usually have gastrointestinal or immediate allergic features rather than dermatitis alone. Zinc deficiency causes periorificial and acral dermatitis with diarrhoea, alopecia or poor growth. Netherton syndrome, Omenn syndrome and other immunodeficiencies are rare but important when erythroderma, hair abnormality, severe infection or failure to thrive occurs.
Cutaneous T-cell lymphoma is extremely rare in children but persistent atypical plaques require dermatology. Drug eruption, photodermatosis and connective-tissue disease enter selected differentials. A poor response is most often explained by insufficient potency, inadequate quantity, incorrect application, infection, contact allergy or wrong diagnosis; escalating blindly is unsafe.
Management
Explain that control, not an instant permanent cure, is the realistic aim. Use a fragrance-free emollient liberally every day and after bathing. Bathe briefly in lukewarm water with a gentle soap substitute when needed, pat dry and apply emollient promptly. Choose an affordable acceptable formulation because the best emollient is one used consistently. Avoid perfume, harsh scrubbing and known reproducible irritants.
Treat active inflammation promptly with a topical corticosteroid of appropriate potency for age, site and severity. Demonstrate amount and duration, separating the anti-inflammatory from the all-over emollient. Face and folds generally need lower potency; thick lichenified sites may require a different supervised plan. Proactive intermittent treatment to recurrent sites may reduce relapses after control. Topical calcineurin inhibitors can be steroid-sparing for selected sensitive sites.
Manage infection based on clinical severity. Localised bacterial infection may need targeted treatment; systemic illness or extensive infection needs systemic assessment. Do not prescribe antibiotics for every weeping flare. Eczema herpeticum needs urgent systemic antiviral treatment and eye assessment when periocular. Wet wraps can help selected severe flares when taught safely, avoiding inappropriate potency under occlusion.
Optimise topical care before systemic escalation. Dermatology-directed phototherapy, biologic or oral immune-modifying therapy requires age, vaccination, infection, laboratory and reproductive checks. Address sleep, school, mental health and caregiver workload. Provide a written flare plan and early review.
Prescribing Information
Emollients are leave-on treatments, soap substitutes or bath products; formulations are not interchangeable in feel or fire risk. Prescribe sufficient quantity and warn that paraffin-containing products can accumulate on fabric and increase flammability: keep away from flames and smoking. Pump dispensers reduce contamination. Stop a product that reproducibly stings or worsens dermatitis and reassess ingredients.
Topical corticosteroid potency, site, age, amount and duration must be explicit. Use fingertip units or another demonstrated measure from a verified paediatric formulary. Appropriate short courses have a favourable safety profile, whereas chronic potent use on face, folds or under occlusion can cause atrophy, striae, ocular effects and systemic absorption. Do not dilute a potent steroid into moisturiser as an improvised lower strength.
Topical calcineurin inhibitors can cause transient burning and require licensed age/site use and sun advice. Do not apply over untreated infection. Antibiotics should be reserved for clinically infected disease and selected by extent, systemic state and local resistance; routine combined steroid-antibiotic use promotes sensitisation and resistance. Sedating antihistamines do not treat skin inflammation and are not routine long-term sleep medicines.
Systemic corticosteroids commonly rebound and are generally unsuitable for chronic eczema. Biologics and JAK inhibitors require specialist selection, current India label verification, infection and vaccination assessment and monitoring. Never reuse an old systemic prescription. Every plan should state maintenance, flare treatment, maximum duration, review and emergency signs.
When to Refer
Same-day emergency assessment is required for suspected eczema herpeticum: rapidly worsening painful eczema, clustered monomorphic vesicles, punched-out erosions, fever, lethargy or eye involvement. Admit or urgently refer extensive bacterial infection with systemic illness, dehydration, erythroderma, blistering or severe pain. Ophthalmology is urgent for periocular herpes, painful red eye or visual symptoms.
Dermatology referral is appropriate when diagnosis is uncertain, disease is severe, recurrently infected, scarring, affecting sensitive sites, or uncontrolled after a documented adequate topical plan with observed technique. Refer before systemic immune-modifying therapy or phototherapy. Patch testing may help when contact allergy is suspected. Allergy referral is targeted to convincing immediate food reaction, anaphylaxis or complex allergy, not eczema severity alone.
Paediatric assessment is needed for poor growth, restricted diet, recurrent unusual infection, chronic diarrhoea, erythroderma or suspected immunodeficiency or nutritional deficiency. Psychological or sleep support may be valuable when itch, bullying, school absence or caregiver exhaustion is substantial.
Referral should include onset, distribution, severity, sleep and quality-of-life effect, photographs with consent, infections, allergy history and an exact treatment inventory including potency, quantity and adherence. Continue safe topical maintenance while waiting. A referral letter without an urgent herpes plan is inadequate.
Red Flags
Painful, rapidly worsening eczema with fever, monomorphic vesicles or punched-out erosions is eczema herpeticum until assessed otherwise. It can disseminate and threaten vision; arrange same-day systemic antiviral evaluation. Eye pain, photophobia, red eye or periocular lesions requires urgent ophthalmology. Do not wait for viral results or treat with topical steroid alone.
Spreading warmth, swelling, pus, severe tenderness, lymphangitis, fever or lethargy suggests significant bacterial infection. Widespread blistering, peeling, mucosal involvement or erythroderma is not routine eczema. Reduced intake, low urine or poor perfusion indicates dehydration or systemic illness.
Poor growth, chronic diarrhoea, recurrent deep or unusual infection, persistent thrush, hair-shaft abnormality or severe dermatitis from early infancy raises nutritional deficiency, immunodeficiency or genodermatosis. Atypical fixed lesions, purpura, ulcers or failure despite observed appropriate therapy should reopen diagnosis.
Urgent risk also arises from treatment: potent steroid used widely or under occlusion, eye exposure, systemic immunosuppression with fever, or severe dietary restriction. Ask caregivers to bring all products. Families need immediate-care instructions for herpes features, systemic illness, painful eye and rapidly spreading infection, plus an early review point for a flare that is simply not settling.
Indian Clinical Context
IAP recommendations support gentle neonatal skin care and avoidance of potentially harmful products in Indian settings. They are useful for barrier principles but do not constitute a complete national childhood atopic-dermatitis treatment pathway. current guidelines stepped care and the 2026 AAD paediatric guideline are international comparators whose medicine availability and licensing must be checked locally.
Heat, sweat, water access, price and cultural oil or herbal use shape care. Ask neutrally what is applied; some oils or fragrances irritate, while abrupt blanket prohibition can undermine trust. Recommend a simple affordable fragrance-free emollient and demonstrate quantity. Families should not be blamed for outdoor pollution or housing constraints.
Potent fixed steroid-antifungal-antibiotic combinations sold without clear counselling are a specific safety concern. Record the active ingredients, stop inappropriate products safely and treat the actual diagnosis. Conversely, steroid fear can produce severe undertreatment. Explain potency, site and stop date in the preferred language and use teach-back.
Advanced biologic and JAK therapy may be inaccessible or have different Indian age approval. Do not imply that an international recommendation creates local entitlement or availability. There is no national prevalence figure asserted here. Publication requires organisational review by the MedNext Clinical Team and reconciliation with the current Indian formulary and referral network.
NMC Competency Mapping
The NMC CBME Curriculum 2024 maps common eczematous disorders in Dermatology Topic 12. DR12.1 requires description of causes and pathogenesis, while DR12.2 addresses clinical features, investigations and management. Paediatric teaching can integrate growth, allergy, infection and family counselling, but should not invent a separate childhood-eczema competency code.
Learners should recognise age-specific atopic dermatitis, assess itch, sleep and extent, and distinguish infection, contact dermatitis, scabies, psoriasis, tinea and nutritional or immune disease. They should explain barrier dysfunction without presenting allergy tests as diagnostic. Examination must include the full skin and systemic growth and infection assessment.
Skills teaching should cover gentle skin care, adequate emollient quantity, topical corticosteroid selection by site and severity, fingertip-unit demonstration, a written flare plan and recognition of eczema herpeticum. Students must counsel against indiscriminate combination creams and unsupervised elimination diets. Prescribing assessment should provide a current formulary.
Integration spans paediatrics, dermatology, immunology, microbiology, nutrition, pharmacology, ophthalmology and communication. A strong case station includes treatment beliefs or access barriers. Mapping to DR12.1-DR12.2 supports education but does not replace specialist review for severe disease or governance approval of this draft.
Key Exam Pearls for NEET PG
Atopic dermatitis is pruritic, chronic and relapsing. Infants often have facial and extensor disease; older children commonly show flexural lichenification. Diagnosis is clinical, and serum IgE neither confirms nor excludes it. Severity includes sleep and quality of life, not body-surface area alone.
Baseline treatment is regular emollient plus prompt site-appropriate topical corticosteroid for flares. Topical calcineurin inhibitors are steroid-sparing at selected sensitive sites. Proactive intermittent anti-inflammatory treatment can prevent recurrent-site flares. Check potency, quantity and technique before declaring treatment failure. Systemic corticosteroids risk rebound and are not routine chronic therapy.
Crusting does not automatically require antibiotics. Painful monomorphic vesicles and punched-out erosions indicate eczema herpeticum and need urgent systemic antiviral assessment; periocular disease threatens vision. Persistent severe disease, growth failure or unusual infection suggests another diagnosis. Food exclusion without a convincing reaction or specialist plan can cause malnutrition.
For NMC, remember Dermatology Topic 12: DR12.1 covers causes and pathogenesis, DR12.2 covers features, investigations and management. In exam answers include barrier repair, correct anti-inflammatory potency, infection red flags and counselling.
High-yield errors are ordering broad allergy panels, recommending routine food exclusion, using antibiotics for colonisation, or calling every treatment failure refractory disease. First verify diagnosis, potency, quantity, application site, duration and adherence. The face and folds need potency caution, while thick lichenified skin may need an adequately potent supervised course. Always separate bacterial infection from eczema herpeticum: the latter is painful, monomorphic and systemically dangerous, and antiviral treatment must not be delayed by a swab.
Frequently Asked Questions
Is childhood eczema caused by a food allergy?
Usually not as a single cause. Food allergy is more frequent in early severe eczema, but positive sensitisation tests do not prove that food drives the rash. Test only for a convincing immediate reaction or specialist question. Unsupervised exclusion diets can impair growth and should not replace skin treatment.
Are topical corticosteroids safe for a child with eczema?
They are generally safe and effective when the correct potency is used on the correct site for a defined duration. Undertreatment also causes harm. A clinician should demonstrate quantity and stop date; potent products require particular caution on face, folds, infants and occluded skin.
Does every crusted eczema flare need an antibiotic?
No. Colonisation and inflammation can produce weeping or crust, while antibiotics are reserved for clinically important infection. Spreading warmth, pus, fever or systemic illness needs assessment. Painful uniform vesicles or punched-out erosions suggest herpes, which requires urgent antiviral care rather than routine antibacterial cream.
When should a child with eczema see a specialist?
Refer for uncertain diagnosis, severe or sensitive-site disease, recurrent infection, poor growth, major sleep or school effect, or failure after an adequate observed topical plan. Painful rapidly spreading vesicles, fever, eye symptoms, blistering or systemic illness require same-day emergency assessment, not a routine appointment.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic